Brain isoprostanes: A marker of lipid peroxidation and oxidative stress in AD

Neurology

Volumn 61, Issue 4, 2003, Pages 436-437

  Irizarry, Michael C ^a   Hyman, Bradley T ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID; AMYLOID BETA PROTEIN; ARACHIDONIC ACID; ASCORBIC ACID; GLUTATHIONE; ISOPROSTANE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; DISEASE MARKER; EDITORIAL; HUMAN; LIPID PEROXIDATION; NERVE FUNCTION; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SENILE PLAQUE; URINALYSIS;

EID: 0042432072     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.61.4.436     Document Type: Editorial

References (12)

1. 2a-VI differentiate AD from frontotemporal dementia. Neurology 2003;61:475-478.
2. Floyd RA. Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med 1999;222:236-245.
3. Perry G, Nunomura A, Hirai K, et al. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? Free Radic Biol Med 2002;33:1475-1479.
4. Cracowski JL, Durand T, Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol Sci 2002;23:360-366.
5. 2-isoprostanes in Alzheimer's disease: Evidence for enhanced lipid peroxidation in vivo. FASEB J 1998;12:1777-1783.
6. Butterfield DA, Castegna A, Lauderback CM, Drake J. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 2002;23:655-664.
7. McLellan ME, Kajdasz ST, Hyman BT, Bacskai BJ. In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J Neurosci 2003;23:2212-2217.
8. Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002;287:3223-3229.
9. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216-1222.
10. Montine TJ, Beal MF, Cudkowicz ME, et al. Increased CSF F2-isoprostane concentration in probable AD. Neurology 1999;52:562-565.
11. 2a-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 2000;48:809-812.
12. 2-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol 2002;52:175-179.